Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Depreciation & Amortization (CF) (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Depreciation & Amortization (CF) data on record, last reported at $608000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) rose 24.85% year-over-year to $608000.0; the TTM value through Sep 2025 reached $2.2 million, up 13.75%, while the annual FY2024 figure was $2.0 million, 12.41% down from the prior year.
  • Depreciation & Amortization (CF) reached $608000.0 in Q3 2025 per ABEO's latest filing, up from $544000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $824000.0 in Q2 2021 and bottomed at $487000.0 in Q2 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $648473.7, with a median of $615000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 60.44% in 2021, then grew 24.85% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $807000.0 in 2021, then decreased by 9.67% to $729000.0 in 2022, then plummeted by 32.65% to $491000.0 in 2023, then increased by 9.78% to $539000.0 in 2024, then rose by 12.8% to $608000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $608000.0 in Q3 2025, $544000.0 in Q2 2025, and $534000.0 in Q1 2025.